DNASE1 and intracerebral hemorrhage: Although DNase I has not yet been clinically applied in intracerebral hemorrhage (ICH), its use as a NET-degrading strategy has demonstrated favorable safety and partial efficacy in clinical studies of cystic fibrosis (259), COVID-19–related ARDS (241), and autoimmune diseases (242).